emjreviews.com50 分钟
Tolebrutinib Targets Chronic Lesions in MS Treatment: ACTRIMS 2025
A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...